Assessment of vertebral microarchitecture in overt and mild Cushing's syndrome using trabecular bone score
Autor: | Renaud Winzenrieth, Nadia Mehsen-Cetre, Amandine Boisson, Virginie Grouthier, Helene Vinolas, Charles Mesguich, Antoine Tabarin, Laurence Bordenave, Thierry Schaeverbeke |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Cortisol secretion medicine.medical_specialty S syndrome business.industry Endocrinology Diabetes and Metabolism Osteoporosis Urology 030209 endocrinology & metabolism medicine.disease 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Endocrinology Normal bone Trabecular bone score Internal medicine Macronodular Adrenal Hyperplasia medicine Etiology business Mace |
Zdroj: | Clinical Endocrinology. 89:148-154 |
ISSN: | 0300-0664 |
DOI: | 10.1111/cen.13743 |
Popis: | OBJECTIVE Osteoporotic fractures associated with Cushing's syndrome (CS) may occur despite normal bone mineral density (BMD). Few studies have described alterations in vertebral microarchitecture in glucocorticoid-treated patients and during CS. Trabecular bone score (TBS) estimates trabecular microarchitecture from dual-energy X-ray absorptiometry acquisitions. Our aim was to compare vertebral BMD and TBS in patients with overt CS and mild autonomous cortisol secretion (MACE), and following cure of overt CS. SETTING University Hospital. DESIGN Monocentric retrospective cross-sectional and longitudinal studies of consecutive patients. PATIENTS A total of 110 patients were studied: 53 patients had CS (35, 11 and 7 patients with Cushing's disease, bilateral macronodular adrenal hyperplasia and ectopic ACTH secretion respectively); 39 patients had MACE (10 patients with a late post-operative recurrence of Cushing's disease and 29 patients with adrenal incidentalomas); 18 patients with non-secreting adrenal incidentalomas. 14 patients with overt CS were followed for up to 2 years after cure. RESULTS Vertebral osteoporosis at BMD and degraded microarchitecture at TBS were found in 24% and 43% of patients with CS, respectively (P |
Databáze: | OpenAIRE |
Externí odkaz: |